Skip to main content
Industry News
Empagliflozin may benefit patients with HFrEF, diabetes
7/31/2020

Researchers evaluated 3,730 patients with heart failure with reduced ejection fraction and found that adding 10 mg of the SGLT2 inhibitor empagliflozin to standard of care led to a reduced risk for a composite of HF hospitalization or cardiovascular death among those with and without diabetes, compared with placebo. The findings will be presented at the European Society of Cardiology Congress.

Full Story: